Story thread · 2 reports / 2 sources

Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial

endpts.com · 11dShare

Latigo Biotherapeutics said its non-opioid drug reduced acute pain in a Phase 2b study, as the company seeks to compete with Vertex Pharmaceuticals’ approved pain treatment Journavx. Next, Latigo has to replicate its findings in ...

First report: STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx — statnews.com, 13d